MTARC1 and liver disorder: Hepatocyte-specific MTARC1 mRNA knockdown is consideredby many actors as a promising strategy for treatment or preventionof liver diseases.26,28,36 Systemic application is always associated with a high risk of sideeffects and drug–drug interactions, whereas targeted therapypromises fewer undesired effects.45 TargetingmARC1 through a liver-specific GalNac-siRNA approach rather than aPROTAC or small-molecule inhibitor could also—to a certainextent—reduce the risk of drug–drug interactions withmARC1 substrates, e.g., NHU, as extrahepatic mARC1 would be unaffectedby this approach.